+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID04181060

Evaluating Osimertinib Alone Versus Osimertinib Plus Bevacizumab for First-Line Treatment of Metastatic EGFR-Mutant Non-Small Cell Lung Cancer

Led by National Cancer Institute (NCI) · Updated on 2026-11-04

300

Participants Needed

604

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of osimertinib and bevacizumab versus osimertinib alone as first-line treatment for patients with advanced non-small cell lung cancer NSCLC that has spread beyond the lungs stage IIIB-IV and involves mutations in the EGFR gene. This phase III trial aims to determine if adding bevacizumab, which stops blood vessel growth to tumors, can better control cancer progression and improve survival compared to osimertinib alone. The study also examines overall survival, response rates, central nervous system progression, and treatment toxicity. Participants are randomly assigned to one of two groups one receives oral osimertinib daily, and the other receives oral osimertinib daily plus bevacizumab intravenously every 21 days. Treatment cycles repeat every 21 days unless disease progression or unacceptable side effects occur. Throughout the study, patients undergo various imaging tests including echocardiography, multigated acquisition scans, computed tomography, and possibly magnetic resonance imaging. Blood and urine samples are also collected to study treatment effects and resistance mechanisms. After finishing treatment, participants are monitored every three months for up to 10 years to track disease progression and survival. The main outcome measured is progression-free survival, defined as the time from starting treatment until cancer worsens or death. Secondary outcomes include overall survival, response rates, central nervous system involvement, and treatment safety. Regular assessments and sample collections help researchers understand how the treatments work and their long-term effects.

CONDITIONS

Brief Title

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here